Adial Pharmaceuticals (NASDAQ:ADIL) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Adial Pharmaceuticals (NASDAQ:ADIL – Free Report) to a sell rating in a research note published on Saturday.

ADIL has been the topic of a number of other reports. Brookline Capital Markets downgraded Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Alliance Global Partners initiated coverage on Adial Pharmaceuticals in a research report on Monday, August 3rd. They set a “buy” rating and a $11.00 price objective for the company. Needham & Company LLC downgraded Adial Pharmaceuticals to a “buy” rating in a report on Monday, June 15th. Loop Capital set a $6.00 target price on Adial Pharmaceuticals in a research report on Monday, June 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $15.62.

Read Our Latest Research Report on Adial Pharmaceuticals

Adial Pharmaceuticals Stock Up 25.4%

Shares of Adial Pharmaceuticals stock opened at $4.99 on Friday. Adial Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $10.75. The company’s 50 day moving average is $3.08 and its 200 day moving average is $2.51. The company has a market cap of $13.12 million, a price-to-earnings ratio of -0.63 and a beta of 1.39.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($11.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($10.22).

Insider Buying and Selling

In related news, major shareholder Coastlands Capital Lp bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were bought at an average cost of $2.60 per share, with a total value of $65,000.00. Following the acquisition, the insider owned 373,322 shares in the company, valued at $970,637.20. This trade represents a 7.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders acquired 36,753 shares of company stock valued at $97,638. 1.86% of the stock is currently owned by company insiders.

Institutional Trading of Adial Pharmaceuticals

Several hedge funds have recently bought and sold shares of ADIL. Jane Street Group LLC raised its stake in shares of Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after buying an additional 109,500 shares during the period. Citadel Advisors LLC purchased a new position in shares of Adial Pharmaceuticals during the 3rd quarter valued at about $51,000. Finally, Armistice Capital LLC bought a new position in shares of Adial Pharmaceuticals during the 4th quarter valued at approximately $562,000. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

(Get Free Report)

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.

Featured Articles